Back

Finerenone in patients with heart failure and diabetic kidney disease: comparison of mineralocorticoid receptor antagonists. FINARM study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (4) - Pharmacotherapy for heart failure (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Edison Omar Boada Lincango

A Coruna University Hospital, A Coruna (Spain)

8 More presentations in this session

Presentation thumbnail
Discussant - Pharmacotherapy for heart failure (1)
Presentation thumbnail
A novel, Pillar-GDMT score for prediction of all-cause mortality in patients with heart failure with reduced ejection fraction requiring heart failure hospitalisation
Doctor B. Muk (Budapest, HU)
Abstract
Presentation thumbnail
SGLT2i and ARNI improve long-term heart failure outcomes: a multi-state model analysis from a real-world southeast asian cohort
Doctor P. Amornritvanich (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Rationale and design of the CADENCE trial: evaluating sotatercept in Cpc-PH secondary to HFpEF
Doctor A. Urbinati (New York, US)
Abstract Slides
Presentation thumbnail
Comparison of the effect of the rapid up-titration programme and the standard care on therapy optimisation at a heart failure outpatient clinic in real-world clinical practice
Doctor F. Banfi-Bacsardi (Budapest, HU)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (4) - Pharmacotherapy for heart failure (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Early experience with finerenone in patients with heart failure and diabetic kidney disease: 6 months of real-world cohort follow-up
thumbnail
Congress Session
HOT LINE 7
thumbnail
Congress Presentation
Finerenone-related risk of hypotension in patients with heart failure with mildly reduced or preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources